The self-pressurising air-Q ® Intubating Laryngeal Airway (aILA-SP, Mercury Medical, Clearwater, FL, USA) is a new supraglottic airway device (SAD), which shares design similarities to the original reusable air-Q ® Intubating Laryngeal Airway (aILA, Mercury Medical, Clearwater, FL, USA), except for the incorporation of a low resistance, communication orifice between the air tube and periglottic cuff. This communication orifice allows the intracuff pressure to dynamically equilibrate with the airway pressure during spontaneous and positive pressure ventilation (personal communication, Dr Dan Cook, inventor of the aILA-SP). Since the cuff is pressurised by dynamic movement of air from the air tube into the cuff and vice versa, there is no need for manual cuff inflation, and the pilot tube and balloon valve have been eliminated (Figure 1 ). Such a cuff may be advantageous insofar as it dynamically adjusts its intracuff pressure and fit with the patient's pharyngeal and periglottic anatomy, which may lead to a reduction in airway morbidity while still providing the high seal pressure (30 cmH 2 O) 1 afforded by the aILA design. Our primary aim was to evaluate the efficacy of the aILA-SP with respect to insertion success, airway seal pressure (ASP) and overall clinical utility described as a composite of its ability to allow adequate ventilation and/or be used as a conduit for tracheal intubation in adults undergoing general anaesthesia.
MATERIALS AND METHODS
After approval by the Minimal Risk Institutional Review Boards of both the University of Wisconsin (Madison, WI, USA) and the University of Washington (Seattle, WA, USA), we performed a retrospective chart review of the first 100 patients in which an aILA-SP was used while undergoing procedures requiring general anaesthesia between October 2010 and March 2012. All devices were placed during routine anaesthetic care by one of the authors, or
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The self-pressurising air-Q ® Intubating Laryngeal Airway is a new, commercially available, supraglottic airway device that incorporates a self-regulating periglottic cuff. In this retrospective review, we describe our initial clinical experience using the device in 100 patients. The ease and number of insertion attempts, airway seal pressure, device positioning, intubation success and oropharyngeal morbidity were recorded.
The air-Q Intubating Laryngeal Airway was successfully inserted in all 100 patients and functioned adequately as a primary airway in 70 of the 72 patients in which it was used for this purpose. The median (interquartile range [range]) airway seal pressure was 22 (19-29, [10-40]) cmH 2 O. Intubation via the air-Q Intubating Laryngeal Airway was successful in 28 of 29 (97%) patients. Eleven percent of patients complained of sore throat postoperatively before discharge. In our series, the air-Q Intubating Laryngeal Airway performed adequately as a primary airway during anaesthesia with respect to ease of insertion, adequacy of airway maintenance and as a conduit for intubation in both anticipated and unanticipated difficult airways. Although our initial experience is positive, further investigation with larger numbers of observations are needed as the upper limits of the 95% confidence intervals for device failure (the worst failure rate the clinician could expect) are still high.
Key Words: air-Q Intubating Laryngeal Airway by an anaesthesia resident or anaesthetist under the direct supervision and guidance of one of the authors, in patients for whom an SAD was chosen as either the appropriate primary airway device, as a conduit for tracheal intubation in known or unanticipated difficult airways, or as a conduit for intubation to be left in place with the tracheal tube through it, obviating the need for a Bailey manoeuvre 2 at the end of the procedure. Prior to the introduction of the aILA-SP, all authors were experienced in the placement of the original aILA in more than 50 patients as both devices use the same placement technique.
Per routine, patients were premedicated with midazolam 1 to 2 mg intravenously just prior to leaving the pre-procedure holding area. Upon arrival in the operating room or radiological suite, standard monitors were applied and patients were pre-oxygenated for three to five minutes with 100% oxygen during normal tidal breathing. Anaesthesia was then induced intravenously using propofol 2 to 3 mg.kg -1 with or without fentanyl 1 to 2 μg.kg -1 . After loss of eyelash reflex, patients were ventilated with sevoflurane 2 to 3% in 100% oxygen until they became unresponsive to a jaw thrust. The precise insertion technique used is as described elsewhere for the original aILA design 1 . With the patient positioned with atlanto-occipital extension, the aILA-SP was placed in the mouth behind the tongue and the index finger of the operator's left hand was used to guide the tip of the cuff around the base of the tongue. Simultaneously, a caudad force was applied with the operator's right hand on the airway tube and the device was rotated inwardly and forward into position. If initial resistance to advancement was met, a jaw lift with the operator's left hand was performed while the device was rotated inwardly and forward into position with the right hand. When further advancement was met by a firm stop, the device was assessed for ventilation adequacy by observing chest rise with manual inflation using the anaesthesia circle system breathing bag and end-tidal carbon dioxide on the anaesthesia gas monitor. If the ventilatory capacity was deemed adequate, the ASP was then measured by closing the airway pressure release valve, increasing the fresh gas flow to 5 l.minute -1 and recording the pressure associated with an audible air leak or up to a maximum reading of 40 cmH 2 O. Whenever clinically indicated (e.g. in the setting of questionable device positioning or planned intubation) or for teaching purposes, the position of the bowl of the mask in relation to the laryngeal inlet was viewed using a fibreoptic bronchoscope placed next to the end of the airway tube and graded. A grade 1 view was documented if a full view of the vocal cords was present. A grade 2 view was documented when a partial view of the vocal cords, including the arytenoids, was present. A grade 3 view was documented if only the epiglottis could be visualised. A grade 4 view was documented if neither of the aforementioned structures could be visualised 3 . If tracheal intubation through the aILA-SP was planned, water-soluble lubricant was applied liberally to the outer distal third and balloon of an appropriately sized tracheal tube (maximum of 7.5 mm and 8.5 mm ID tracheal tubes for size 3.5 and 4.5 aILA-SPs, respectively). A neuromuscular blocking agent was administered and tracheal tube placement through the aILA-SP was attempted using either a blind and/or fibreoptic-aided technique. When blind intubation through the aILA-SP was attempted, the aILA-SP circuit adapter was removed, a lubricated tracheal tube was passed gently through the device to a depth of 21 to 23 cm measured at the patient's teeth, and connected to the anaesthesia breathing circuit. Tracheal intubation was confirmed by observing chest rise with manual inflation using the anaesthesia circle system breathing bag, end- tidal carbon dioxide on the anaesthesia gas monitor and bilateral breath sounds on chest auscultation. If resistance was met during blind tracheal tube insertion, the tracheal tube was withdrawn slightly and rotated 45 to 90° counterclockwise and repeat advancement was attempted. If further resistance was met, the tracheal tube was withdrawn such that only 18 cm of its length was inserted in the aILA-SP and conversion to a fibreoptic-aided technique was performed. When fibreoptic-aided intubation through the aILA-SP was undertaken, the aILA-SP circuit adapter was removed and a lubricated tracheal tube was placed immediately in the aILA-SP to a depth of 18 cm. A fibreoptic bronchoscope was then passed through the tracheal tube and aILA-SP into the trachea. The tracheal tube was then railroaded over the fibrescope. If any resistance was met during tracheal tube advancement, the tube was rotated in 90° increments counterclockwise until suitable tube advancement occurred. Correct tracheal tube positioning was then confirmed using the fibrescope to observe tracheal rings and the carina distal to the end of the tracheal tube. Secondarily, tracheal intubation was confirmed by also observing chest rise with manual inflation using the anaesthesia circle system breathing bag, end-tidal carbon dioxide on the anaesthesia gas monitor and bilateral breath sounds on chest auscultation. After confirming ventilation through the tracheal tube, the aILA-SP was either removed using a size 1 ILA Removal Stylet (Mercury Medical, Clearwater, FL, USA) or left in situ if use of the aILA-SP for emergence was planned.
Overall clinical usefulness was defined as follows: excellent=easy aILA-SP insertion, excellent quality ventilation as judged by the attending anaesthesiologist, easy tracheal intubation (if attempted) and no intraoperative events requiring device repositioning or replacement; good=slightly difficult aILA-SP insertion, adequate quality ventilation as judged by the attending anaesthesiologist, successful tracheal intubation (if attempted) and no intraoperative events requiring device repositioning or replacement; fair=any need for intraoperative repositioning but no replacement of the device, but slightly difficult tracheal intubation (if attempted); inadequate=unsuccessful aILA-SP insertion, inadequate ASP for device use as primary airway for the case, inability to perform tracheal intubation (if attempted) or intraoperative events requiring device replacement.
Data were analysed using Prism 5.0a (GraphPad Software, Inc., La Jolla, CA, USA). Intergroup comparisons of continuous variables were performed using two-sided, unpaired, t-test or Mann-Whitney test. Chi-square and Fisher's exact (two-sided) tests were used for intergroup comparisons of categorical variables. Confidence intervals (CI) for device failure rates, when used as a primary airway, an intubation conduit and the combined endpoint of either, were constructed using an online calculator for the modified Wald method (www.graphpad.com/ quickcalcs/ConfInterval1.cfm). Statistical significance was defined as a P value <0.05. Data are reported as number (%), mean (standard deviation) or median (interquartile range, [range]), unless otherwise noted.
RESULTS
A total of 100 aILA-SP devices were placed in 100 patients. Overall patient and procedure characteristics are presented in Table 1 , while device and performance characteristics are presented in Table 2 .
The aILA-SP was placed as a primary airway in 72 cases with two failures noted (failure rate 2.7% [95% CI 0.2, 10]). The ASP was 22 (19-29, [10-40]) cmH 2 O. In one instance of placement failure, a sufficient ASP (>10 cmH 2 O) to provide adequate ventilation for the case could not be obtained despite multiple placement attempts. In this case, an alternative SAD was successfully placed and used. In the other instance of placement failure, a patient could not be adequately ventilated via an aILA-SP due to decreased pulmonary compliance, despite an ASP of 19 cmH 2 O. This patient was easily intubated through the aILA-SP.
Overall intubation success using the aILA-SP as a conduit for tracheal tube placement was 97% (n=29; failure rate 3.4% [95% CI 0, 19]). Blind intubation was attempted eight times, was successful on the first attempt in six cases and was rescued in one case using a fibrescope after two blind intubation attempts (failure rate 33% [95% CI 0.4, 94]). The remaining patient could not be intubated via the aILA-SP after blind attempts, but the ASP was 30 cmH 2 O. As such, the aILA-SP was used, instead of a tracheal tube, as the primary airway for the case. Fibreoptic-aided intubation was successful in 21 of 22 cases (failure rate 5% [95% CI 0, 24]). One patient could not be intubated via the aILA-SP despite fibreoptic-aid due to periglottic tissue obstruction.
After device removal, mild blood-staining was noted in six instances and moderate blood-staining in two instances. On questioning in the post-anaesthesia care unit, mild sore throat was reported by seven patients and moderate sore throat by four patients.
Overall clinical usefulness was judged excellent or good in 94%, fair in 4% and poor in 3% of patients. Table 3 compares patients receiving size 3.5 vs 4.5 devices. As predicted, patients receiving size 3.5 aILA-SPs were more often female and smaller (weight, height and body mass index). However, no intergroup differences in age, American Society of Anesthesiologists physical status, ASP, initial attempt insertion success, ease of insertion, grade 1 glottic view or ease of intubation were found.
DISCUSSION
Our main findings were that the aILA-SP performed adequately in an overwhelming majority of patients when used as a primary airway during maintenance of anaesthesia and as a conduit for tracheal intubation. While insertion times were not routinely measured, the ease of placement and number of insertion attempts is similar to that reported for the aILA 1, 4 . In addition, our reported insertion success in ≤2 attempts (99%) is similar to that reported in two recent paediatric studies specifically evaluating the aILA-SP 5-6 . While the median ASP we report is higher than that reported for children (22 vs 16 to 18 cmH 2 O), which may be due to greater variance in airway anatomy from birth to childhood, it is lower than that previously reported for the aILA 1, 4 .
With regard to using the aILA-SP as a conduit for intubation, our overall success rates for both blind and fibreoptic-aided intubation are comparable to two recent prospective randomised trials, which compared it to the Fastrach Intubating Laryngeal Mask Airway (LMA North America, San Diego, CA, USA) and reported a 95 to 98% success rate [7] [8] .
Eleven percent of patients complained of sore throat during their post-anaesthetic recovery period, which appears to be substantially less than the incidence of oropharyngolaryngeal complaints previously reported for the latest generation aILA (sore throat 46%, pain on swallowing 30%) 1, 4 . We could postulate that this is a result of the performance of the self-pressurising cuff of the aILA-SP, rather than the manually inflated cuff of the aILA, which essentially eliminates the chance of cuff over-inflation and pressure-related morbidity. Although this is possible, our study is limited by its retrospective nature and small number of observations. With respect to oropharyngolaryngeal complaints, it is possible that a lack of notation in the medical record regarding sore throat complaints in the postoperative recovery area indicates that specific questions were either not asked or complaints not documented. This would have resulted in an underestimation of the true incidence. However, asking about and noting the presence of throat complaints is standard at both authors' institutions and so we believe that if this was the case, the effect is small. Additionally, our report only includes 100 cases. The upper limits of our reported confidence intervals suggest that "the worst we can expect" 9 from the aILA-SP as a primary airway, as a conduit for intubation or a composite endpoint of either is a failure rate of approximately 10, 24 and 10%, respectively. If this represents a true failure rate, even the most liberal of practitioners would be unlikely to incorporate the device into routine clinical use. Our results, therefore, should be interpreted as documentation of the device feasibility and to provide data for sample size calculations of future investigations. Depending on the 'acceptable' device failure rate, some recommendations regarding the minimum number of observations that must be included can be made for a 1, 2 and 5% failure rate, which are 560, 221 and 110, respectively. This is, of course, independent of whether failure as a primary airway, as a conduit for intubation or a combination of both is the primary outcome of interest.
In conclusion, we report the first clinical observations in adults of the use of the aILA-SP. The aILA-SP is a newer product, structurally similar to the aILA and should provide similar quality ventilation and access to the trachea without the need for cuff inflation. While the lack of a pilot balloon is not new, the concept of a self-regulating cuff is unique among currently marketed SADs. In our experience, the device was easily inserted and functioned adequately for airway maintenance during anaesthesia. In addition, as a conduit for intubation, the aILA-SP achieved a high rate of intubation success. Our data should be used to plan further studies of the device, which should focus on attaining adequate power to truly assess its clinical utility. 
